Endometrial receptivity with different support protocols for the luteal phase in ovarian stimulation cycles in which final oocyte maturation is carried out with GnRH analogues. Analysis by endometrial microarrays.

IVI Madrid0 个研究点开始时间: 2011年8月2日最近更新: 2012年3月19日

适应症

试验速览

暂无简介。

•1.Aged between 18 and 34 years old.
•2.Ovule donors admitted in the IVI Oocyte Donor Program - Madrid.
•3.Conventional ovarian stimulation protocol.
•4.Normal XX karyotype.
•5.Body mass index (BMI) between 18 and 25 kg / m2.
•6.Negative serologies for Hepatitis B surface antigens (HBs Ag), antibodies for the Hepatitis C virus (HC Hb) and Human Immunodeficiency Virus (HIV) prior to donation.
•7.Normal cervical cytology in the past year.
•8.General informed consent signed by the patients or their legal representative.
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 25
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•1.Any clinical condition that counterindicates or prevents being able to carry out an endometrial biopsy.
•2.Hypersensitivity, allergy or intolerance to any of the medications prescribed in each of the treatment groups.
•3.Participation in another clinical trial at the time of donation.
•4.Any serious concomitant illness which, according to investigator´s opinion, may compromise the study or affect patients´ tolerability with regard to this treatment.

发起方

IVI Madrid